AlphAIalphai — Financial news for AI agents
financialcontent.comAUG 46 min read$AHCO

AdaptHealth (NASDAQ:AHCO) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops 25.7%

AdaptHealth Corp. (NASDAQ:AHCO) reported Q2 CY2026 revenue of $740.3 million, down 7.5% year on year, below analyst estimates. Full-year revenue guidance was $2.87 billion at the midpoint, 17.7% below consensus. GAAP EPS was a loss of $0.99, and the stock fell 25.7% to $8.05 after results.

Original reporting
financialcontent.com
Published Aug 4, 2026, 12:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 12:37 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
AdaptHealth (NASDAQ:AHCO) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops 25.7% — source image
Source · financialcontent.com
Decision brief

The 30-second read

$AHCOBearishHigh
01

Why it matters

Q2 revenue decline plus full-year revenue guidance materially below consensus, alongside a deeper GAAP loss and sharp same-day selloff, increases the probability of downward estimate revisions and near-term multiple compression.

02

Market read

This is a direct earnings and guidance miss with quantified shortfalls versus consensus and an immediate 25.7% stock drop, making it actionable for trading around estimate revisions.

03

What to watch

The text highlights margin deterioration (adjusted operating margin negative in Q2) but does not break out drivers (pricing, utilization, mix, or cost actions), which could change the forward outlook if clarified.

Relevance 9/10Novelty 9/10Timing: post-earnings, same-day after reporting

Background

AdaptHealth is a home medical equipment and services provider with a large US footprint, and the article frames its recent slowdown versus prior multi-year growth.

Company-level read

Ticker impact

$AHCOBearishHigh confidence
Context

AdaptHealth reported Q2 CY2026 revenue of $740.3M, down 7.5% YoY, and full-year guidance $2.87B midpoint 17.7% below estimates.

Expected impact

Bearish bias for the next several sessions, with volatility elevated around any follow-up guidance or analyst revisions.

Evidence & confidence

The article provides concrete, time-sensitive datapoints: revenue decline, guidance materially below consensus, EPS loss of -$0.99, and an immediate 25.7% stock drop to $8.05.

Market effects

Sector

Weak results in home healthcare services can pressure sentiment toward similarly levered, margin-sensitive providers.

Regional

Primarily US healthcare services sentiment; limited direct regional spillover described.

Global

No explicit global linkage beyond US analyst expectations and healthcare demand narrative.

Counterpoint

What could challenge this read

Despite the miss, the article notes analysts expect revenue growth of 12.1% over the next 12 months, suggesting a potential inflection if execution improves.

Key entities

  • public_company
    AdaptHealth Corp.

    NASDAQ-listed home medical equipment and services provider reporting Q2 CY2026 results and full-year guidance.

  • market_participants
    Wall Street analysts

    Consensus reference for revenue and EPS estimates used to judge the miss and set expectations for forward revisions.

Read at source← All news

Also covered by

1 outlet

Related articles

AUG 15
$AHCOMedAI 8/10

AdaptHealth Cuts 2026 Outlook as Contract Costs Hit Margins

AdaptHealth Corp. (AHCO) cut its 2026 adjusted EBITDA outlook to $490 million to $520 million from $680 million to $730 million, citing margin pressure from West Coast capitated contract costs and a manufacturer price increase. Revenue guidance is $2.85 billion to $2.89 billion. Q2 organic revenue rose 15.9% to $740.3 million. The company agreed to sell Diabetes Health for $235 million.

mychesco.com6 min
AUG 11
$AHCOHighAI 9/10

AdaptHealth (AHCO) Q2 2026 Earnings Call Transcript

AdaptHealth (AHCO) reported Q2 2026 net revenue of $740.3 million, up 12.7% year over year, with organic revenue growth of 15.9%. Adjusted EBITDA was $132 million, down 3.2%, and full-year revenue guidance was cut to $2.85-$2.89 billion with adjusted EBITDA of $490-$520 million. The company cited West Coast contract costs and a $30 million supplier price headwind, plus a $235 million diabetes divestiture.

fool.com7 min
AUG 11
$AHCOMed

AdaptHealth Sells Diabetes Unit to Sharpen Focus on Sleep, Respiratory Growth

AdaptHealth (NASDAQ:AHCO) said it will sell its diabetes unit to focus on sleep and respiratory. The deal is expected to leave about $60 million of overhead costs in continuing operations, with roughly half removed in year one. Q2 revenue grew 16%, including West Coast expansion, while the company works on contract onboarding and supplier rebate terms.

yahoo.com6 min
AUG 9
$AHCOHighAI 9/10

Why AdaptHealth Stock Plummeted This Week

AdaptHealth (NASDAQ: AHCO) shares fell about 47% this week after the company reported Q2 results below expectations and issued sharply lower guidance. Analysts expected EPS of $0.15; AdaptHealth posted a loss of $1.07 per share. Sales rose 12.7% to $740.3M but missed forecasts. Full-year sales guidance was cut to $2.85B-$2.89B and EBITDA and FCF ranges were reduced.

yahoo.com2 min
AUG 6
$AHCOHighAI 9/10

AdaptHealth Shares Sink After Earnings Miss and Lower Full-Year Guidance

AdaptHealth Corp. (NASDAQ:AHCO) shares fell about 13% premarket after Q2 2026 results missed expectations and the company cut full-year guidance. It reported a net loss of $0.99 per share and revenue of $740.3M versus $848.9M expected. FY revenue guidance was lowered to $2.85B-$2.89B from about $3.49B, with adjusted EBITDA $490M-$520M and free cash flow $80M-$120M.

yahoo.com4 min